Literature DB >> 35729481

The role of the PTEN/mTOR axis in clinical response of rectal cancer patients.

Oya Orun1, Sevgi Özden2, Olca Kılınç3, Pınar Mega Tiber3, Pelin Yonar3, Zerrin Özgen4, Hazan Özyurt2.   

Abstract

BACKGROUND: Preoperative chemoradiotherapy has long been accepted as a method to improve survival and lifetime quality of rectal cancer patients. However, physiologic effects of these therapies largely depend on the resistance of cells to the radiation, type of chemotherapeutic agents and individual responses. As one of the signaling cascades involved in chemo- or radiation- resistance, the present study focused on several proteins involved in pTEN/Akt/mTOR pathway to explore their prognostic significance.
MATERIALS AND METHODS: Samples from advanced stage rectal cancer patients were analyzed to detect expression levels of pTEN/Akt/mTOR pathway related proteins pTEN, mLST8, REDD1, BNIP3, SAG and NOXA, together with p53, by RT-qPCR. Kaplan-Meier analysis was used to assess expression-survival relation and correlations among all proteins and clinicopathological features were statistically analyzed.
RESULTS: Except p53, none of the proteins showed prognostic significance. High p53 expression presented clear impact on overall survival and disease free survival. It was also significantly related to pathologic complete response. p53 showed high correlation to local recurrence as well. On the other hand, strong correlation was observed with PTEN expression and tumor response, but not with survival. High associations were also observed between mLST8/REDD1, PTEN and NOXA, confirming their role in the same cascade.
CONCLUSION: The contentious role of p53 as a prognostic biomarker in colorectal cancer was further affirmed, while PTEN and REDD1 could be suggested as potential candidates. Additionally, NOXA emerges as a conjunctive element for different signaling pathways.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  NOXA; PTEN; REDD1; Rectum cancer; mLST8; mTOR; p53

Mesh:

Substances:

Year:  2022        PMID: 35729481     DOI: 10.1007/s11033-022-07665-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  46 in total

1.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

2.  DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin ligase and regulates survival and autophagy.

Authors:  Yongchao Zhao; Xiufang Xiong; Yi Sun
Journal:  Mol Cell       Date:  2011-10-21       Impact factor: 17.970

3.  Effects of PTEN on the proliferation and apoptosis of colorectal cancer cells via the phosphoinositol-3-kinase/Akt pathway.

Authors:  Yan Sun; Hua Tian; Lin Wang
Journal:  Oncol Rep       Date:  2015-02-16       Impact factor: 3.906

4.  Small RING Finger Proteins RBX1 and RBX2 of SCF E3 Ubiquitin Ligases: The Role in Cancer and as Cancer Targets.

Authors:  Dongping Wei; Yi Sun
Journal:  Genes Cancer       Date:  2010-07

5.  Prognostic role of sensitive-to-apoptosis gene expression in rectal cancer.

Authors:  Sevgi A Ozden; Hazan Ozyurt; Zerrin Ozgen; Olca Kilinc; Mustafa Oncel; Aylin E Gul; Nimet Karadayi; Nedime Serakinci; Beki Kan; Oya Orun
Journal:  World J Gastroenterol       Date:  2011-11-28       Impact factor: 5.742

Review 6.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

7.  The association of apoptotic protein expressions sensitive to apoptosis gene, p73 and p53 with the prognosis of cervical carcinoma.

Authors:  Pinar Mega Tiber; Latife Baloglu; Sevgi Ozden; Zerrin Ozgen; Hazan Ozyurt; Makbule Eren; Oya Orun
Journal:  Onco Targets Ther       Date:  2014-11-26       Impact factor: 4.147

8.  Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.

Authors:  Andrea Sartore-Bianchi; Federica Di Nicolantonio; Michele Nichelatti; Francesca Molinari; Sara De Dosso; Piercarlo Saletti; Miriam Martini; Tiziana Cipani; Giovanna Marrapese; Luca Mazzucchelli; Simona Lamba; Silvio Veronese; Milo Frattini; Alberto Bardelli; Salvatore Siena
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

9.  Predictive and prognostic factors in colorectal cancer: a personalized approach.

Authors:  Myutan Kulendran; John F Stebbing; Christopher G Marks; Timothy A Rockall
Journal:  Cancers (Basel)       Date:  2011-03-29       Impact factor: 6.639

Review 10.  Posttranslational regulation of Akt in human cancer.

Authors:  Chia-Hsin Chan; Ukhyun Jo; Abraham Kohrman; Abdol Hossein Rezaeian; Ping-Chieh Chou; Christopher Logothetis; Hui-Kuan Lin
Journal:  Cell Biosci       Date:  2014-10-01       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.